lifecycl
intracellular
pathogen
especi
virus
intim
tie
macromolecular
synthet
process
host
cell
case
positivestrand
rna
virus
abil
translat
thu
replic
infect
genom
depend
upon
hijack
host
protein
identifi
protein
particip
west
nile
viru
wnv
replic
test
abil
sirna
design
knockdown
express
larg
subset
human
gene
interfer
replic
wnv
replicon
report
multipl
sirna
proteasom
subunit
interf
wnv
genom
amplif
specif
interfer
shown
demonstr
silenc
proteasom
subunit
interfer
venezuelan
equin
enceph
viru
replicon
drug
block
proteasom
activ
potent
inhibitor
wnv
genom
amplif
even
cell
treat
h
infect
indic
proteasom
requir
postentri
stage
wnv
infect
cycl
genu
flaviviru
within
famili
flavivirida
consist
multipl
virus
particular
import
public
health
includ
yellow
fever
viru
japanes
enceph
viru
dengu
viru
west
nile
viru
wnv
virus
respons
signific
morbid
mortal
worldwid
wnv
first
becam
public
health
concern
unit
state
introduc
new
york
citi
sinc
report
case
diseas
associ
wnv
infect
case
present
sever
neurolog
patholog
result
nearli
death
center
diseas
control
prevent
unfortun
mani
flavivirus
approv
antivir
therapi
control
wnv
diseas
yet
approv
vaccin
protect
wnv
diseas
similar
member
genu
wnv
genom
consist
positivesens
singlestrand
rna
approxim
kilobas
length
genom
encod
mere
protein
nonstructur
c
prmm
e
seven
nonstructur
brinton
demonstr
play
role
replic
viral
genom
lindenbach
et
al
due
limit
amount
genet
materi
carri
wnv
like
virus
expect
depend
upon
mani
compon
macromolecular
machineri
host
cell
consequ
expect
wnv
protein
viral
genom
must
interact
multitud
host
protein
infect
cell
effici
reproduc
fact
sever
interact
variou
stage
wnv
infect
identifi
one
first
virushost
interact
occur
interact
viru
particl
receptor
host
cell
surfac
promot
viral
entri
recent
report
suggest
wnv
entri
may
mediat
part
integrin
chu
ng
dcsign
davi
et
al
result
intern
viru
via
clathrindepend
endocyt
pathway
chu
ng
infect
viru
also
facilit
bind
cellsurfac
heparan
sulfat
gilfoy
mason
lee
lobig
three
differ
host
protein
translat
elong
cell
intracellular
protein
tiar
shown
interact
stem
loop
wnv
genom
blackwel
brinton
blackwel
brinton
li
et
al
interact
tiar
wnv
report
interfer
wnvinduc
stress
granul
format
process
bodi
assembl
emara
brinton
site
translat
control
mrna
aggreg
degrad
time
stress
addit
src
kinas
cye
demonstr
import
host
protein
involv
wnv
particl
releas
infect
cell
activ
appear
manifest
level
particl
traffick
endoplasm
reticulum
extracellular
space
hirsch
et
al
virolog
ubiquitinproteasom
system
ubiquit
extralysosom
protein
degrad
system
clear
unneed
protein
cytosol
nucleu
play
key
role
vast
number
normal
cellular
process
includ
remov
misfold
abnorm
protein
cellular
stress
respons
remov
unneed
protein
cell
differenti
cell
cycl
regul
cellular
immun
respons
ciechanov
glickman
ciechanov
protein
target
degrad
tag
ubiquitin
coval
bond
produc
three
enzymat
entiti
activ
enzym
carrier
enzym
ligas
ultim
bind
ubiqutin
onto
protein
glickman
ciechanov
nandi
et
al
monoor
polyubiquin
protein
traffick
proteasom
degrad
eukaryot
proteasom
ubiquit
highli
conserv
multiproteas
complex
consist
barrelshap
proteolyt
core
complex
proteasom
regulatori
complex
cap
one
end
groll
et
al
perkin
et
al
tanaka
et
al
voge
et
al
proteasom
compos
two
copi
seven
alpha
subunit
seven
beta
subunit
arrang
stack
ring
two
outer
ring
contain
alpha
subunit
import
control
entri
exit
protein
well
bind
specif
regulatori
protein
two
inner
ring
hand
compos
beta
subunit
repres
catalyt
activ
site
proteasom
nandi
et
al
three
primari
proteolyt
activ
attribut
proteasom
trypsinlik
activ
cleavag
hydrophob
amino
acid
chymotryspinlik
activ
cleavag
basic
amino
acid
caspaselik
cleavag
acid
amino
acid
eukaryot
proteasom
proteas
activ
associ
specif
beta
subunit
respect
kisselev
et
al
nussbaum
et
al
interestingli
mammal
special
form
proteasom
evolv
three
catalyt
beta
subunit
replac
differ
catalyt
subunit
demartino
gillett
proteasom
refer
immunoproteasom
replac
constitut
proteasom
follow
immun
stimul
respons
gener
antigen
peptid
display
class
major
histocompat
complex
mhc
baumeist
et
al
goldberg
et
al
rock
et
al
life
cycl
virus
intim
tie
life
cycl
cell
therefor
unsurpris
virus
evolv
mechan
hinder
host
respons
parasit
host
function
replic
member
multipl
famili
rna
dna
virus
shown
modul
ubiquitinproteasom
system
advantag
varieti
reason
includ
immun
evas
viral
entri
releas
transcript
regul
apoptosi
inhibit
bank
et
al
gao
luo
shackelford
pagano
mani
virus
includ
human
cytomegaloviru
kikkert
et
al
shamu
et
al
epstein
barr
viru
levitskaya
et
al
sever
herp
virus
bonam
stevenson
coscoy
et
al
interfer
process
mhc
class
peptid
ubiquitinproteasom
system
shown
facilit
entri
transport
incom
influenza
viru
khor
et
al
minut
viru
ro
et
al
ro
kempf
murin
coronaviru
yu
lai
releas
hiv
viral
progeni
requir
proteasom
activ
presum
allow
effici
process
gag
protein
viral
proteas
therebi
facilit
virion
bud
plasma
membran
patnaik
et
al
schubert
et
al
strack
et
al
addit
proteasom
inhibit
markedli
reduc
coxsackieviru
group
viral
rna
protein
synthesi
level
result
decreas
releas
progeni
viru
luo
et
al
demonstr
wnv
genom
amplif
either
genom
replic
genom
translat
sensit
disrupt
proteasom
function
largescal
sirna
screen
human
gene
discov
silenc
two
differ
alpha
subunit
proteasom
sirna
result
dramat
reduct
wnv
genomedriven
firefli
luciferas
fluc
activ
addit
use
specif
proteasom
inhibitor
demonstr
inhibit
proteasom
result
reduct
wnv
antigen
level
wnv
protein
accumul
progeni
viru
yield
inhibit
observ
follow
treatment
inhibitor
preand
postinfect
indic
wnv
util
proteasom
post
entri
step
replic
cycl
silenc
proteasom
subunit
result
reduct
wnv
fluc
veev
fluc
activ
aid
identifi
host
protein
facilit
wnv
infect
andor
genom
amplif
librari
sirna
screen
abil
suppress
firefli
luciferas
fluc
signal
encod
wnv
viral
replicon
particl
vrp
fayzulin
et
al
vrp
replicon
viral
genom
lack
sequenc
structur
gene
packag
particl
structur
protein
provid
tran
packag
cell
wnv
vrp
particularli
use
mimic
wnv
infect
genom
amplif
nearli
aspect
howev
packag
replicon
encod
structur
gene
vrp
infect
produc
progeni
virion
thu
vrp
use
easili
studi
infect
andor
genom
amplif
independ
assembl
releas
addit
unabl
spread
beyond
initi
infect
cell
vrp
safe
use
biosafeti
level
condit
sirna
librari
util
studi
human
druggabl
genom
librari
purchas
ambion
consist
individu
sirna
design
silenc
approxim
gene
cell
stabli
express
renilla
luciferas
rluc
transfect
sirna
infect
wnv
vrp
express
fluc
wnv
fluc
vrp
h
later
assay
fluc
wnv
vrp
infectiongenom
amplif
rluc
cell
number
activ
h
post
infect
studi
identifi
candid
gene
transfect
individu
sirna
cell
result
greater
reduct
rlucnorm
wnvdepend
fluc
activ
result
reduct
rluc
activ
greater
data
publish
elsewher
valid
candid
gene
obtain
screen
gene
librari
sever
confirmatori
test
perform
util
sirna
correspond
gene
three
individu
sirna
gene
assay
inhibit
wnv
fluc
vrp
activ
addit
human
cell
line
hela
sknsh
cell
also
test
abil
reduc
activ
encod
wnv
vrp
fayzulin
et
al
reduc
antigen
synthesi
live
wnv
ensur
candid
gene
import
specif
wnv
infect
sirnatransfect
cell
infect
flucencod
venezuelan
equin
enceph
viru
veev
vrp
test
abil
sirna
inhibit
infect
andor
genom
amplif
alphaviru
final
confirm
pool
individu
sirna
target
candid
gene
purchas
second
sourc
dharmacon
assay
cell
secondari
screen
result
approxim
confirm
candid
gene
data
publish
elsewher
interestingli
confirm
candid
gene
subunit
proteasom
fact
individu
sirna
ambion
pool
sirna
dharmacon
target
two
alpha
subunit
shown
consist
reduc
wnv
infect
genom
amplif
decreas
rlucnorm
fluc
activ
transfect
cell
littl
effect
cell
number
fig
show
exampl
typic
silenc
experi
show
transfect
pool
sirna
dharmacon
target
either
dramat
lower
wnv
replicondriven
fluc
activ
compar
cell
transfect
nontarget
control
sirna
neg
fig
howev
veev
replicondriven
fluc
activ
impair
follow
transfect
either
sirna
fig
indic
specif
sirna
interfer
addit
although
flucspecif
sirna
reduc
fluc
express
deriv
wnv
veev
vrp
sirna
target
wnv
genom
expect
specif
wnv
replicondriven
fluc
activ
fig
transfect
sirna
also
result
greater
reduct
wnv
antigen
express
follow
live
wnv
infect
data
shown
confirm
effect
sirna
western
blot
analysi
perform
sirnatransfect
cell
lysat
analysi
indic
transfect
sirna
result
reduc
express
respect
compar
neg
control
wnvspecif
sirna
transfect
fig
interestingli
transfect
either
sirna
result
decreas
express
subunit
although
express
specif
target
gene
alway
demonstr
greater
knockdown
even
silenc
one
subunit
effect
steadi
state
level
subunit
proteasom
possibl
destruct
subunit
stabil
assembl
multimolecul
complex
abil
one
sirna
target
also
partial
recogn
vice
versa
demonstr
correspond
decreas
wnv
antigen
express
follow
silenc
membran
also
probe
wnvspecif
antibodi
result
show
dramat
reduct
express
wnv
follow
transfect
wnv
sirna
compar
transfect
neg
sirna
fig
sirna
technolog
power
tool
studi
gene
function
howev
due
potenti
offtarget
silenc
effect
birmingham
et
al
jackson
et
al
lin
et
al
qiu
et
al
scacheri
et
al
valid
result
treat
hela
cell
two
differ
proteasom
inhibitor
potent
cellperm
revers
inhibitor
chymotrypsinlik
activ
proteasom
borissenko
groll
cell
treat
infect
wnv
hfluc
vrp
assay
fluc
activ
wnv
antigen
accumul
elisa
cell
viabil
cell
viabilitycel
number
measur
two
method
mtt
assay
assay
cellexpress
rluc
activ
simplifi
present
result
mtt
valu
shown
although
rluc
activ
correl
well
mtt
valu
case
hela
cell
pretreat
littl
show
mark
reduct
wnvdriven
fluc
activ
wnv
elisa
antigen
express
compar
mockor
dmsotreat
cell
fig
addit
treatment
littl
fig
result
greater
inhibit
wnv
activ
compar
dmso
vehicl
treatment
although
inhibitor
appear
less
effect
inhibit
wnv
vrp
infectiongenom
amplif
cell
compar
hela
cell
treatment
result
substanti
lower
fluc
activ
wnv
elisa
antigen
express
compar
mock
dmso
treatment
treatment
effect
cell
led
greater
reduct
wnv
activ
littl
fig
pretreat
concentr
result
approxim
reduct
wnv
activ
fig
consist
inabl
psmaspecif
sirna
impair
veev
vrpdriven
fluc
activ
cell
demonstr
littl
reduct
veev
vrpdriven
fluc
activ
compar
mocktreat
cell
data
shown
throughout
experi
highest
concentr
either
hela
cell
result
major
chang
cellular
characterist
reduct
cell
viabil
measur
either
mtt
assay
fig
rluc
activ
result
shown
monitor
wnv
antigen
express
anoth
method
help
ensur
specif
sensit
elisa
assay
hela
cell
infect
wnv
hfluc
vrp
cell
monolay
harvest
assay
express
western
blot
analysi
consist
fig
studi
treatment
hela
cell
result
reduct
wnv
protein
express
lowest
drug
dose
test
fig
addit
treatment
result
reduct
wnv
protein
express
compar
mockor
dmsotreat
cell
although
consist
fluc
elisa
detect
method
see
fig
effect
express
less
observ
treatment
fig
antibodi
consist
recogn
two
band
lower
band
correspond
predict
molecular
weight
approxim
top
band
may
repres
uncleav
level
serv
load
control
similar
treatment
group
except
panel
nontarget
neg
control
neg
sirna
wnvspecif
flucspecif
sirna
transfect
cell
incub
h
infect
veev
fluc
vrp
wnv
hfluc
vrp
addit
h
respect
cell
monolay
assay
fluc
activ
wnv
veev
replic
level
rluc
activ
cell
number
valu
shown
fluc
normal
rluc
compar
mocktransfect
cell
error
bar
repres
standard
deviat
mean
three
independ
experi
asterisk
repres
statist
signific
compar
neg
sirna
transfect
p
b
panel
b
monolay
sirnatransfect
cell
harvest
assay
western
blot
level
wnv
load
control
reduct
observ
consist
cytotox
observ
dose
ifa
perform
proteasom
inhibitortr
hela
cell
consist
western
blot
analysi
fig
treatment
hela
cell
reduc
detect
level
fig
fig
although
appear
effect
consist
previou
studi
interestingli
appear
effect
block
protein
accumul
although
signific
known
fig
ifa
perform
proteasom
inhibitortr
cell
show
similar
reduct
level
result
shown
dapi
phalloidin
counterstain
indic
inhibitortr
cell
nuclear
abnorm
major
defect
overal
cellular
architectur
argu
nonspecif
effect
inhibitor
wnv
genom
amplif
sinc
revers
inhibitor
proteasom
possibl
determin
whether
remov
inhibitor
treatment
cell
would
return
wnv
infectiongenom
amplif
level
observ
mocktreat
cell
type
experi
help
ensur
inhibitor
treatment
result
perman
damag
cellular
process
might
respons
inhibitorinduc
inhibit
wnv
vrp
infect
genom
amplif
end
hela
cell
pretreat
approxim
h
drug
remov
cell
infect
wnv
hfluc
vrp
follow
h
recoveri
period
consist
fig
fig
hela
fig
cell
incub
demonstr
dosedepend
reduct
wnvdepend
fluc
activ
wnv
elisa
antigen
accumul
howev
wnv
hfluc
vrp
infectionrepl
fig
hela
fig
cell
treatment
wash
nearli
ident
mockor
dmsotreat
cell
dose
inhibitor
data
suggest
treatment
inhibitor
indirect
effect
cell
abil
support
wnv
vrp
genom
amplif
ascertain
whether
proteasom
inhibitor
serv
block
wnv
vrp
entri
later
stage
infect
hela
cell
treat
either
concurr
wnv
hfluc
vrp
infect
variou
time
postinfect
assay
wnvdepend
fluc
activ
wnv
antigen
accumul
surprisingli
treatment
inhibitor
either
late
h
post
infect
result
reduct
wnvdepend
fluc
antigen
accumul
fig
b
fact
h
postinfect
inhibit
wnv
activ
nearli
extent
observ
drug
ad
prior
infect
howev
inhibitori
effect
inhibitor
wnv
genom
amplif
appear
wane
later
time
postinfect
reduct
wnv
activ
h
post
infect
highest
dose
drug
fig
consist
pretreat
studi
treatment
fig
effect
timepoint
test
fig
although
wnv
vrp
mimic
wnv
infect
import
examin
effect
proteasom
inhibitor
treatment
live
wnv
infect
well
sinc
proteasom
inhibitor
treatment
effect
abil
wnv
hfluc
vrp
infect
cell
monolay
hela
cell
infect
wnv
h
prior
treatment
assay
wnv
accumul
supernat
fluid
h
later
titrat
perform
supernat
harvest
treat
cell
indic
proteasom
inhibitor
treatment
dramat
reduc
product
infecti
wnv
particl
fig
treatment
hela
cell
observ
wnv
vrp
experi
slightli
less
effect
impair
wnv
product
compar
treatment
howev
treat
cell
still
demonstr
near
reduct
secret
infecti
particl
compar
mocktreat
cell
littl
fig
hand
demonstr
inhibit
wnv
particl
releas
similar
concentr
fig
inhibit
wnv
releas
consist
inhibit
wnv
vrpinduc
fluc
activ
wnv
antigen
accumul
data
indic
inhibit
proteasom
activ
cell
line
sever
impair
wnv
genom
amplif
suggest
proteasom
import
cellular
cofactor
wnv
replic
mani
rna
virus
requir
specif
host
factor
effici
replic
wnv
except
beyond
host
machineri
requir
entri
translat
receptor
present
cell
surfac
chu
ng
davi
et
al
medigeshi
et
al
acidif
endosom
chu
ng
translat
factor
davi
et
al
wnv
like
requir
addit
host
protein
establish
environ
permiss
effici
replic
exampl
interact
wnv
stem
loop
structur
two
host
protein
tiar
li
et
al
shown
interfer
cell
abil
form
stress
granul
effect
prevent
host
cell
shut
viral
cellular
translat
emara
brinton
report
proteasom
may
serv
essenti
cofactor
wnv
replic
cycl
ubiquitinproteasom
system
primari
mechan
intracellular
extralysosom
protein
degrad
play
key
role
varieti
cell
function
includ
cell
cycl
regul
antigen
process
transcript
regul
apoptosi
signal
transduct
transcript
regul
ciechanov
glickman
ciechanov
goldberg
et
al
nandi
et
al
involv
vast
array
function
surpris
multipl
virus
evolv
mechan
manipul
system
advantag
influenza
viru
shown
util
ubiquitinproteasom
system
effici
traffick
late
endosomelysosom
stage
viru
entri
khor
et
al
mous
hepat
viru
coronoviru
minut
viru
parvoviru
also
shown
util
proteasom
system
traffick
cytoplasm
yu
lai
nucleu
ro
et
al
ro
kempf
respect
multipl
member
herpesvirida
famili
evolv
differ
mechan
manipul
ubiquitinproteasom
pathway
whether
encod
ubiquitin
ligaselik
protein
coscoy
et
al
target
specif
protein
destruct
coscoy
et
al
kikkert
et
al
parkinson
et
al
prosch
et
al
inhibit
proteasom
activ
shown
impair
coxsackieviru
replic
luo
et
al
recent
report
indic
coxsackievirusinduc
activ
extracellular
signalregul
kinas
erk
pathway
requir
replic
luo
et
al
reduc
follow
proteasom
inhibit
wong
et
al
suggest
possibl
mechan
proteasom
action
ubiquitinproteasom
pathway
also
appear
critic
factor
lifecycl
hiv
well
effici
process
gag
polyproteinand
subsequ
releas
matur
hiv
particlesi
depend
upon
ubiquitinproteasom
activ
patnaik
et
al
schubert
et
al
strack
et
al
studi
describ
result
attempt
identifi
novel
host
factor
involv
wnv
infect
andor
genom
amplif
studi
base
unbias
screen
host
factor
systemat
knock
nearli
human
gene
use
librari
sirna
throughout
initi
screen
process
multipl
confirmatori
screen
silenc
multipl
differ
subunit
proteasom
dramat
reduc
wnv
infect
andor
genom
amplif
fact
sirna
target
two
alpha
subunit
consist
knock
wnv
vrp
infect
andor
genom
amplif
level
greater
compar
nontarget
neg
control
sirna
similar
screen
perform
live
wnv
also
show
silenc
proteasom
subunit
neg
effect
wnv
infectiongenom
amplif
krishnan
et
al
consist
result
show
posttransl
silenc
two
proteasom
gene
could
impair
wnv
replic
show
treatment
cell
micromolar
concentr
two
wellcharacter
proteasom
inhibitor
result
impair
activ
wnv
vrp
live
wnv
indic
function
proteasom
requir
wnv
genom
amplif
small
number
candid
gene
identifi
less
follow
confirmatori
test
somewhat
startl
howev
librari
consist
rel
small
subset
gene
gene
gene
encod
human
genom
current
known
involv
mani
differ
diseas
process
even
within
subset
gene
like
mani
overlook
due
presenc
compensatori
pathway
express
homologu
failur
specif
sirna
effici
silenc
target
although
silenc
mani
differ
proteasom
subunit
effect
wnv
activ
initi
sirna
librari
screen
perform
two
gene
consist
knockdown
wnv
activ
secondari
screen
puzzl
howev
believ
like
due
qualiti
sirna
initi
librari
mention
sirna
equal
effect
especi
firstgener
sirna
optim
modifi
enhanc
activ
use
initi
sirna
librari
thu
like
sirna
proteasom
subunit
either
specif
effect
silenc
target
gene
compar
sirna
proteasom
compos
mani
differ
subunit
multipl
opportun
silenc
express
thu
appear
type
multisubunit
complex
particularli
well
suit
discoveri
functionbas
sirna
screen
strategi
discuss
introduct
virus
shown
manipul
ubiquitinproteasom
pathway
enhanc
viral
activ
variou
stage
viru
lifecycl
includ
entri
postentri
traffick
translat
transcript
matur
releas
posttreat
wnv
vrpinfect
cell
sever
impair
wnv
vrp
genom
amplif
indic
proteasom
requir
viral
entri
fact
effect
inhibitor
wnv
vrp
activ
h
post
infect
suggest
unlik
proteasom
requir
endosom
traffick
wnv
particl
uncoat
viral
rna
shown
influenza
khor
et
al
mous
hepat
viru
yu
lai
time
wnv
life
cycl
well
establish
expect
vari
cell
type
process
viral
entri
genom
unpackag
like
occur
within
first
h
wnv
positivestrand
rna
viru
newli
unpackag
genom
transport
cellular
membran
immedi
translat
cellular
machineri
viral
protein
produc
suffici
level
replic
complex
form
begin
replic
viral
genom
serv
sourc
templat
translat
cell
type
detect
low
level
wnv
antigen
littl
h
post
infect
suggest
presenc
activ
translat
like
replic
time
point
although
know
precis
proteasom
involv
lifecycl
effect
h
post
infect
suggest
act
level
either
translat
genom
replic
shown
proteasom
inhibit
result
reduct
wnv
yield
howev
test
whether
seen
hiv
martinserrano
schubert
et
al
strack
et
al
proteasom
directli
involv
packag
andor
releas
wnv
progeni
virion
studi
exclud
possibl
proteasom
involv
stage
infect
howev
initi
studi
demonstr
impair
wnv
genom
amplif
perform
wnv
vrp
packag
thu
proteasom
involv
sole
packag
releas
viral
progeni
instead
like
impair
wnv
particl
releas
observ
due
decreas
either
treat
h
drug
remov
cell
infect
wnv
vrp
cell
assay
fluc
activ
wnv
antigen
express
cell
viabil
valu
shown
percent
mock
error
bar
repres
standard
deviat
mean
three
independ
experi
protein
deriv
translat
genom
produc
genom
replic
consist
indirect
assay
fluc
elisa
total
level
wnv
measur
western
blot
analysi
dramat
reduc
follow
proteasom
inhibitor
treatment
wnv
complex
serv
viral
proteas
requir
proper
process
viral
polyprotein
subsequ
genom
replic
possibl
proteasom
inhibitor
proteasom
could
effect
proteas
activ
howev
although
decreas
express
detect
viral
protein
appear
abnorm
band
pattern
associ
impair
protein
process
proteasom
inhibitortr
cell
result
shown
suggest
unlik
inhibit
proteasom
direct
neg
effect
viral
polyprotein
process
ifa
studi
reveal
curiou
result
expect
decreas
express
presenc
inhibitor
readili
detect
howev
appear
though
effect
express
pronounc
effect
could
sever
reason
curiou
effect
possibl
antibodi
sensit
antibodi
particularli
treatment
also
possibl
viral
protein
differ
turnov
rate
locat
within
secretori
pathway
infect
cell
may
also
concentr
antigen
make
visibl
nevertheless
data
clearli
demonstr
role
proteasom
postentri
stage
wnv
infect
although
yet
determin
whether
reduct
antigen
accumulationexpress
due
direct
inhibit
viral
translat
inhibit
viral
genom
replic
would
also
reduc
translat
product
reason
behind
proteasom
import
clear
ubiquitinproteasom
system
involv
varieti
normal
cellular
process
includ
signal
transduct
transcript
proteasom
inhibit
impair
wnv
particl
releas
monolay
hela
cell
infect
wnv
h
viru
remov
indic
concentr
ad
infect
cell
twentyfour
hour
post
infectiontreat
supernat
remov
treat
cell
titrat
sampl
determin
ihc
see
materi
method
result
shown
percent
viru
titer
mocktreat
cell
error
bar
repres
standard
deviat
mean
three
independ
experi
regul
immun
respons
apoptosi
could
tie
wnv
replic
although
wnv
shown
sever
group
interfer
signal
prevent
phosphoryl
guo
et
al
scholl
mason
impair
shown
achiev
degrad
specif
protein
recent
medigeshi
et
al
demonstr
wnv
induc
degrad
transcript
factor
associ
er
proteasomedepend
fashion
medigeshi
et
al
howev
studi
perform
live
wnv
h
post
infect
perform
wnv
vrp
h
post
infect
hand
wnv
vrp
infect
caus
observ
apoptosi
h
post
infect
associ
proteasom
inhibit
wnv
vrp
replic
genom
amplif
degrad
may
interest
investig
nevertheless
possibl
wnv
target
specif
protein
proteasom
disrupt
degrad
neg
impact
wnv
genom
amplif
ident
protein
investig
detail
role
proteasom
could
also
link
format
defect
ribosom
product
drip
process
translat
sequenc
encod
viral
cellular
genom
produc
function
protein
mani
chanc
introduct
error
mistak
includ
addit
incorrect
amino
acid
earli
even
late
termin
translat
product
improp
fold
splice
protein
error
result
format
drip
yewdel
yewdel
et
al
yewdel
nicchitta
expect
incorrect
product
would
rapidli
degrad
proteasom
could
potenti
interfer
function
normal
protein
cellular
process
thu
accumul
wnvgener
drip
condit
rapid
viral
polyprotein
accumul
within
replic
complex
could
interfer
replic
viral
genom
remov
damageddefect
product
could
reason
effici
proteasom
function
requir
wnv
replic
cell
hela
cell
propag
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
antibiot
solut
cell
stabli
express
renilla
luciferas
rluc
use
studi
see
refer
simpli
hela
cell
throughout
studi
bhk
cell
fayzulin
et
al
util
wnv
vrp
prepar
maintain
dmem
supplement
fb
antibiot
solut
puromycin
rlucexpress
cell
gener
infect
cell
monolay
vesticular
stomat
viru
vsv
lentiviru
pseudotyp
viru
express
rluc
blasticidin
resist
kindli
provid
r
davey
utmb
briefli
monolay
cell
plate
tissu
cultur
plate
infect
pseudotyp
viru
twentyfour
hour
postinfect
blasticidin
ad
media
cell
incub
approxim
week
antibiot
select
pool
antibioticresist
cell
harvest
propag
normal
growth
media
confirm
integr
function
rluc
gene
cell
test
rluc
activ
describ
live
wnv
util
studi
lowpassag
viru
recov
bhk
cell
transfect
synthet
rna
deriv
infecti
cdna
clone
human
isol
texa
rossi
et
al
viru
recov
bhk
cell
pass
one
time
vero
cell
obtain
stock
use
experi
two
differ
wnv
vrp
util
sirna
screen
vrp
contain
wnv
replicon
express
either
fluc
gene
gene
follow
code
region
insert
c
encod
region
wnv
genom
fayzulin
et
al
proteasom
inhibit
studi
wnv
hfluc
vrp
util
instead
wnv
fluc
vrp
vlp
contain
replicon
ident
except
contain
fluc
gene
deriv
promega
optim
effici
express
human
cell
wnv
vrp
gener
describ
previous
fayzulin
et
al
titer
stock
viru
wnv
vrp
determin
focu
format
assay
vero
cell
previous
describ
gilfoy
mason
veev
replicon
encod
gfp
fluc
control
two
separ
subgenom
promot
veerelucgfp
packag
vrp
describ
previous
volkova
et
al
kindli
provid
frolov
utmb
calbiochem
proteasom
inhibitor
calbiochem
initi
dilut
dmem
serial
dilut
dmem
supplement
dmso
diluent
control
fifti
microlit
inhibitor
dilut
dmso
dmem
alon
ad
monolay
hela
cell
plate
well
plate
incub
approxim
h
infect
wnv
vrp
vrp
infect
wnv
hfluc
vrp
ad
well
top
proteasom
inhibitor
incub
h
sinc
vrp
spread
past
initi
infect
cell
necessari
remov
vrp
infect
unless
otherwis
note
inhibitor
remain
cell
monolay
entir
length
experi
cell
transfect
dharmacon
plu
smartpool
nontarget
sirna
neg
control
neg
sirna
dharmacon
dharmacon
plu
smartpool
sirna
dharmacon
pool
sequenc
gcuagacuguuauguaauu
gggcaggauucaucaaauu
ccauuggaauuguugguaa
gauaccaacacaacgauau
dharmacon
plu
smartpool
sirna
dharmacon
pool
sequenc
gcauauagguuugguguac
acacaaaguagaaccaauu
gaaugagggacgaccauau
caaauggugugguauuagc
briefli
sirna
achiev
nm
final
concentr
incub
dharmacon
transfect
reagent
dilut
dharmacon
cell
cultur
reagent
dccr
dharmacon
min
room
temperatur
complex
ad
well
plate
cell
concentr
cellml
ad
complex
incub
approxim
h
follow
incub
period
transfect
cell
infect
wnv
vrp
describ
sirna
transfect
secondari
confirmatori
screen
perform
case
ambion
sirna
librari
transfect
similar
describ
except
sirna
lyophil
onto
plate
rehydr
plate
dilut
dccr
media
cell
monolay
infect
wnv
vrp
express
fluc
remov
approxim
h
postinfect
cell
mix
luciferas
substrat
mixtur
steadyglo
luciferas
substrat
promega
lysi
buffer
mm
tricin
mm
magnesium
acet
mm
dtt
mm
edta
triton
agit
light
output
lyse
cell
measur
either
appli
biosystem
centro
xs
lb
micropl
luminomet
berthold
technolog
reduc
cost
ambion
sirna
librari
subsequ
secondari
screen
assay
fluc
activ
use
selfprepar
fluc
substrat
describ
previous
fayzulin
et
al
case
immedi
follow
measur
fluc
activ
rluc
substrat
mm
edta
mm
tri
coelenterazin
ctz
nanolight
technolog
ad
directli
well
plate
agit
light
output
lyse
cell
measur
one
luminomet
describ
monolay
sirnatransfect
cell
plate
plate
rins
phosphatebuff
salin
solut
pb
harvest
lysi
buffer
mm
nacl
mm
tri
ph
protein
concentr
determin
biorad
c
protein
assay
biorad
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
transfer
immobilon
polyvinyliden
difluorid
transfer
membran
millipor
describ
previous
gilfoy
mason
membran
probe
mous
antiactin
sigma
rabbit
santa
cruz
goat
antiwnv
r
system
follow
incub
horseradish
peroxidas
hrp
conjug
secondari
immunoglobulin
igg
origin
speci
antibodi
kpl
hrp
decor
band
visual
describ
previous
gilfoy
mason
wnv
antigen
express
measur
elisa
previous
describ
rossi
et
al
briefli
fix
cell
rehydr
block
buffer
pb
contain
normal
hors
serum
nh
incub
antiwnv
mhiaf
polyclon
antibodi
follow
incub
hrplabel
goat
antimous
igg
kpl
tmb
sigma
ad
plate
follow
color
develop
reaction
stop
addit
hcl
absorb
measur
nm
cell
viabil
determin
standard
mtt
assay
short
monolay
treat
cell
incub
mgml
methylthiazolyldiphenyltetrazolium
bromid
mtt
sigma
solut
h
follow
incub
solut
remov
isopropanol
ad
solubil
metabol
mtt
product
plate
agit
min
room
temperatur
absorb
mtt
product
measur
nm
yield
reduct
assay
perform
previous
describ
gu
et
al
briefli
monolay
hela
cell
infect
wnv
moi
approxim
h
follow
treatment
dilut
either
dilut
mem
contain
dmso
cell
supernat
harvest
treat
cell
assay
viru
yield
vero
cell
monolay
describ
gu
et
al
monolay
hela
cell
treat
infect
wnv
hfluc
vlp
describ
treat
cell
monolay
fix
paraformaldehyd
follow
permeabil
fix
monolay
incub
block
buffer
bovin
serum
albumin
normal
hors
serum
mm
glycin
pb
min
probe
use
follow
monoclon
polyclon
antibodi
mous
eiji
kobe
univers
kobe
japan
goat
r
system
alexa
fluor
goat
antimous
igg
invitrogen
alexa
fluor
donkey
antigoat
igg
invitrogen
follow
secondari
antibodi
incub
cell
counterstain
dapi
ngml
alexa
fluor
phalloidin
r
davey
utmb
nuclei
actin
filament
respect
monolay
mount
use
vectashield
vector
laboratori
stain
cell
analyz
zeiss
lsm
uv
meta
laser
scan
confoc
microscop
utmb
infecti
diseas
toxicolog
optic
imag
core
facil
